383
Participants
Start Date
December 21, 2023
Primary Completion Date
December 31, 2025
Study Completion Date
December 31, 2025
64Cu-SAR-bisPSMA
All Patients will receive a single administration, a bolus injection of 200MBq 64Cu-SAR-bisPSMA.
RECRUITING
Fiona Stanley Hospital, Murdoch
RECRUITING
Mount Sinai Doctors Urology Faculty Practice, New York
RECRUITING
Carolina Urologic Research Center, Myrtle Beach
RECRUITING
Mayo Clinic- Jacksonville, Jacksonville
RECRUITING
Urology Associates of Nashville, Nashville
NOT_YET_RECRUITING
Indiana University School of Medicine, Indianapolis
RECRUITING
BAMF Health, Grand Rapids
RECRUITING
Corewell Health, Grand Rapids
RECRUITING
University of Wisconsin, Madison
RECRUITING
Mayo Clinic- Rochester, Rochester
RECRUITING
NorthShore University Health System, Glenview
RECRUITING
XCancer Omaha LLC, Omaha
RECRUITING
Urologic Specialists, Tulsa
RECRUITING
Urology Clinics of North Texas, Dallas
RECRUITING
The Urology Place, San Antonio
RECRUITING
Intermountain Health, Murray
RECRUITING
Mayo Clinic- Phoenix, Phoenix
RECRUITING
Greater Los Angeles VA Medical Center, Los Angeles
RECRUITING
Oregon Urology, Springfield
RECRUITING
Stanford University Medical Center, Stanford
RECRUITING
University of Texas Southwestern Medical Center, Dallas
RECRUITING
St. Vincent's Sydney, Sydney
RECRUITING
Princess Alexandra Hospital, Woolloongabba
Lead Sponsor
Clarity Pharmaceuticals Ltd
INDUSTRY